Affiliation:
1. Jordan University of Science and Technology Faculty of Medicine
2. October 6 University Faculty of Medicine
3. Harvard Medical School Department of Global Health and Social Medicine
4. Jordan University of Science and Technology
Abstract
AbstractIntroduction: Stroke is a leading cause of morbidity and mortality worldwide, with limited effective treatment options. Fingolimod has been shown to have neuroprotective effects in previous studies and has been approved for use in multiple sclerosis. This systematic review aims to evaluate the current evidence regarding the efficacy of Fingolimod in cerebrovascular stroke.Methods: A comprehensive literature search was conducted using electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) for studies published up to January 2023. Studies were included if they evaluated the efficacy of Fingolimod in subjects with cerebrovascular stroke and reported outcomes.Results: This meta-analysis included six studies with a total of 251 patients, 124 in the fingolimod group and 127 in the control group. Fingolimod was associated with significant improvements in NIHSS scores on days 7, 14, 30, and 90 post-stroke, with the greatest improvement seen after one month (MD = -7.1, 95% CI [-9.73, -4.65], P < 0. 00001). Additionally, fingolimod was associated with significant reductions in mRS scores after three months (MD = 7.3, 95% CI [3.06, 17.40], P < 0. 00001) and significant improvements in Modified Barthel Index scores on days 7, 14, 30, and 90 post-stroke. After three months, the mean difference in Modified Barthel Index scores was 14.6 (95% CI [5.80, 23.36], P = 0.0005). Fingolimod was also associated with significant reductions in microvascular permeability ratio (rT%) and infarct volume (MD = -15.2, 95% CI [-23.33, -7.15], P < 0. 00001).Conclusion: The current evidence suggests that Fingolimod may have potential as a neuroprotective agent in cerebrovascular stroke. However, more high-quality clinical trials are warranted.
Publisher
Research Square Platform LLC
Reference44 articles.
1. The global burden of stroke: persistent and disabling;Gorelick PB;The Lancet Neurology,2019
2. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022;Feigin VL;Int J Stroke,2022
3. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis;Asch CJJ;The Lancet Neurology,2010
4. Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke;Hacke W;The New England journal of medicine. 2008 Sep
5. How to make better use of thrombolytic therapy in acute ischemic stroke;Donnan GA;Nature reviews Neurology. 2011 Jun